Two Sigma Investments LP Raises Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Two Sigma Investments LP grew its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 252,939 shares of the biopharmaceutical company's stock after purchasing an additional 45,518 shares during the quarter. Two Sigma Investments LP owned approximately 0.16% of Ocular Therapeutix worth $2,160,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. MetLife Investment Management LLC increased its position in Ocular Therapeutix by 2.7% in the fourth quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock worth $792,000 after buying an additional 2,454 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in Ocular Therapeutix by 10.0% in the 4th quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company's stock worth $237,000 after acquiring an additional 2,526 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Ocular Therapeutix by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock worth $755,000 after acquiring an additional 2,853 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock valued at $285,000 after acquiring an additional 3,347 shares during the period. Finally, Cetera Investment Advisers lifted its holdings in Ocular Therapeutix by 0.6% during the fourth quarter. Cetera Investment Advisers now owns 723,840 shares of the biopharmaceutical company's stock valued at $6,182,000 after purchasing an additional 4,342 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Analysts Set New Price Targets

OCUL has been the subject of several recent research reports. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Needham & Company LLC dropped their target price on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a report on Tuesday, March 4th. Finally, William Blair initiated coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $16.25.

Insider Activity at Ocular Therapeutix

In other news, Director Richard L. Md Lindstrom acquired 10,000 shares of the business's stock in a transaction dated Thursday, May 8th. The stock was purchased at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the acquisition, the director now owns 172,704 shares of the company's stock, valued at $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Pravin Dugel sold 21,219 shares of the stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the transaction, the insider now owns 3,499,099 shares in the company, valued at $25,123,530.82. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,079 shares of company stock valued at $208,739 over the last three months. 2.30% of the stock is owned by corporate insiders.

Ocular Therapeutix Price Performance

Shares of OCUL stock traded up $0.22 on Tuesday, reaching $8.33. The company's stock had a trading volume of 2,951,070 shares, compared to its average volume of 1,407,828. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78. The stock's 50 day simple moving average is $7.38 and its 200-day simple moving average is $7.89. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.33 billion, a P/E ratio of -6.31 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. As a group, equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.